Teladoc (TDOC) AI Stock Analysis

• Market Cap: $1.42B
• Dividend Yield: N/A
• Average Volume (3M): 3.77M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: -2.37%
• EPS Growth: 77.85%
• Country: US
• Employees: 4,620
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.28
• Shares Outstanding: 177,473,400
• 10 Day Avg. Volume: 3,673,982
• 30 Day Avg. Volume: 3,774,858
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 0.60
• P/FCF Ratio: 5.48
• Enterprise Value/Market Cap: 1.19
• Enterprise Value/Revenue: 0.67
• Enterprise Value/Gross Profit: 0.95
• Enterprise Value/Ebitda: -56.70
• 1Y Price Target: $9.05
• Price Target Upside: 19.55% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 14
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $6.50 ▼(-14.13% Downside)

Teladoc's overall stock score reflects significant financial and technical challenges. The company's persistent losses and negative valuation metrics weigh heavily on the score. While the earnings call provided some positive insights, such as exceeding revenue guidance and international growth, these are overshadowed by the bearish technical indicators and ongoing operational inefficiencies.

Positive Factors

Product Innovation

Teladoc's focus on product innovation, such as launching Wellbound and enhancing health programs, strengthens its competitive position and service offerings, potentially leading to increased customer engagement and market share.

International Expansion

International expansion is a key growth driver for Teladoc, with significant revenue contribution, enhancing its global footprint and diversifying its revenue streams, which is crucial for long-term growth.

Integrated Care Segment Growth

Growth in the Integrated Care segment indicates strong demand and effective service delivery, supporting Teladoc's strategy to expand comprehensive healthcare solutions and improve market penetration.

Negative Factors

Declining Revenue Growth

Declining revenue growth reflects challenges in maintaining market momentum and could impact Teladoc's ability to scale efficiently, posing risks to future profitability and market competitiveness.

BetterHelp Revenue Decline

The decline in BetterHelp revenue and user base highlights challenges in the mental health segment, potentially affecting Teladoc's growth prospects and necessitating strategic adjustments.

Increased Customer Acquisition Costs

Rising customer acquisition costs and higher churn rates indicate inefficiencies in user retention strategies, which could pressure margins and hinder sustainable growth.

Teladoc Business Overview & Revenue Model

Company Description

Teladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.

How the Company Makes Money

Teladoc generates revenue primarily through subscription fees and per-visit payments for telehealth services. The company operates under a business model that includes contracts with employers, health plans, and health systems, allowing them to provide telehealth services to their members or employees. Key revenue streams include membership fees from companies that offer Teladoc services as part of their employee benefits package, as well as fees charged for individual consultations. Additionally, Teladoc has formed significant partnerships with various health insurers and healthcare providers, enhancing its service offerings and expanding its market reach, which contributes to its overall earnings.

Teladoc Financial Statement Overview

Summary

Teladoc faces significant financial challenges, with declining revenue growth and persistent losses impacting profitability. While the company has managed to maintain a stable gross profit margin and improve its cash flow position, negative net margins and return on equity highlight ongoing operational inefficiencies. The balance sheet shows moderate leverage, but profitability remains a concern.

Income Statement

Teladoc's income statement reveals a challenging financial landscape. The company has experienced declining revenue growth, with a significant drop in the TTM period. Gross profit margins remain healthy at over 70%, but the net profit margin is negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Despite these challenges, the company has managed to maintain a stable gross profit margin over time.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, which has improved in the TTM period, indicating better leverage management. However, the return on equity is negative, highlighting profitability issues. The equity ratio remains stable, suggesting a balanced asset structure, but the overall financial health is weakened by persistent losses.

Cash Flow

Teladoc's cash flow statement shows some positive trends, with a notable increase in free cash flow growth in the TTM period. The operating cash flow to net income ratio has improved, indicating better cash generation relative to net losses. However, the free cash flow to net income ratio suggests that cash flow improvements are not yet sufficient to cover net losses fully.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.53B	2.57B	2.60B	2.41B	2.03B	1.09B
Gross Profit	1.76B	1.82B	1.84B	1.66B	1.38B	703.13M
EBITDA	-29.69M	31.72M	43.61M	-7.54M	-31.42M	-354.49M
Net Income	-223.59M	-1.00B	-220.37M	-13.66B	-428.79M	-485.14M
Balance Sheet
Total Assets	2.88B	3.52B	4.39B	4.70B	17.73B	17.76B
Cash, Cash Equivalents and Short-Term Investments	726.25M	1.30B	1.12B	918.18M	896.02M	786.57M
Total Debt	1.04B	1.58B	1.59B	1.59B	1.28B	1.48B
Total Liabilities	1.49B	2.03B	2.07B	2.39B	1.69B	1.87B
Stockholders Equity	1.39B	1.49B	2.33B	2.31B	16.05B	15.88B
Cash Flow
Free Cash Flow	198.70M	282.89M	193.67M	172.81M	185.46M	-79.55M
Operating Cash Flow	292.52M	293.68M	350.02M	189.29M	193.99M	-53.51M
Investing Cash Flow	-261.33M	-124.05M	-156.35M	-167.74M	-72.98M	-590.98M
Financing Cash Flow	-550.70M	8.31M	10.85M	6.50M	40.95M	859.14M

Teladoc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.57
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TDOC, the sentiment is Positive. The current price of 7.57 is above the 20-day moving average (MA) of 7.33, above the 50-day MA of 7.50, and below the 200-day MA of 7.65, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 54.08 is Neutral, neither overbought nor oversold. The STOCH value of 70.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TDOC.

Teladoc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSTM	69 Neutral	$686.82M	33.93	5.87%	0.52%	3.68%	5.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMWL	51 Neutral	$87.26M	-0.72	-38.35%	―	4.33%	50.50%
SOPH	51 Neutral	$325.67M	-4.48	-86.09%	―	13.66%	-2.65%
HCAT	50 Neutral	$168.34M	-1.58	-31.33%	―	4.64%	-17.17%
EVH	48 Neutral	$448.64M	-2.64	-13.63%	―	-16.65%	-71.92%
TDOC	47 Neutral	$1.42B	-5.92	-15.42%	―	-2.37%	77.85%

Teladoc Corporate Events

Teladoc Board Member J. Eric Evans to Retire

On December 11, 2025, J. Eric Evans announced his decision to retire from Teladoc Health’s Board of Directors, effective after the 2026 Annual Meeting of Stockholders. Mr. Evans, who has served since 2023, is stepping down for personal reasons, with no disagreements with the company, marking a leadership transition for Teladoc.

The most recent analyst rating on (TDOC) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Teladoc stock, see the TDOC Stock Forecast page.

Teladoc Amends Incentive Plan to Increase Shares

On December 9, 2025, Teladoc Health, Inc. amended its 2023 Employment Inducement Incentive Award Plan to increase the number of shares reserved for issuance by 1,780,000, bringing the total to 7,280,000 shares. This amendment, made without stockholder approval per NYSE Rule 303A.08, reflects the company’s strategic move to enhance its stock-based incentive offerings, potentially impacting its employee retention and attraction strategies.

The most recent analyst rating on (TDOC) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Teladoc stock, see the TDOC Stock Forecast page.

Teladoc CFO Mala Murthy to Resign in November

Teladoc Health announced that its Chief Financial Officer, Mala Murthy, will resign effective November 21, 2025, to pursue an opportunity outside the healthcare industry. The company has begun searching for a new CFO and will implement an interim leadership structure to ensure a smooth transition. In addition, Teladoc reaffirmed its full-year 2025 financial outlook and provided preliminary third-quarter financial results, reporting $626.4 million in revenue and $69.9 million in adjusted EBITDA.

The most recent analyst rating on (TDOC) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Teladoc stock, see the TDOC Stock Forecast page.